BELITE BIO INC - AMER

Belite Bio to Participate in Four Upcoming Investor Conferences

12 May 2025 05:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on May 14, 2025, to Discuss First Quarter 2025 Financial Results

07 May 2025 05:00:01 By Nasdaq GlobeNewswire

Belite Bio Announces Poster Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting

29 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

17 Mar 2025 03:00:34 By Nasdaq GlobeNewswire

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

17 Mar 2025 03:00:02 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

11 Mar 2025 00:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Leerink Partners Global Healthcare Conference

04 Mar 2025 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Interim Analysis Results from the Pivotal Global Phase 3 DRAGON trial of Tinlarebant in Adolescent Stargardt Disease Subjects

26 Feb 2025 23:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Registered Direct Offering of $15 Million

05 Feb 2025 19:35:00 By Nasdaq GlobeNewswire

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

11 Nov 2024 22:00:25 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results

05 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds

03 Nov 2024 13:00:27 By Nasdaq GlobeNewswire

Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

14 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit

08 Oct 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease

10 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio to Participate in Three Upcoming Investor Conferences

03 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

01 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update

09 Aug 2024 13:30:00 By Nasdaq GlobeNewswire

Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

08 Aug 2024 05:00:00 By Nasdaq GlobeNewswire

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results

05 Aug 2024 16:10:54 By Nasdaq GlobeNewswire